Eplontersen
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Conditions
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Trial Timeline
Nov 30, 2022 → Aug 1, 2029
NCT ID
NCT05667493About Eplontersen
Eplontersen is a phase 3 stage product being developed by AstraZeneca for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05667493. Target conditions include Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05667493 | Phase 3 | Recruiting |
Competing Products
9 competing products in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Nucresiran + Vutrisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |
| ALN-TTRSC04 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |
| Inotersen + Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |